提尔泽帕提德诱导的胃肠道表现:系统性审查和元分析
Hani Raka Karrar1, Mahmoud Ismail Nouh1,2, Yousef Ismail Nouh3
1Pharmaceutical Care, Dr. Samir Abbas Hospital, Jeddah, SAU.
Cureus
|November 1, 2023
概括
提尔泽帕提德显著增加了2型糖尿病患者的恶心和腹等胃肠道副作用. 需要进一步的研究来减轻这些常见的不良事件,并提高治疗耐受性.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 蒂尔泽帕提德是一种针对2型糖尿病的新型药物,旨在改善血糖控制并促进减肥.
- 临床试验表明,与蒂尔泽帕提德使用相关的潜在胃肠道 (GI) 副作用.
- 了解这些胃肠道表现的频率和严重程度对于患者管理至关重要.
研究的目的:
- 系统地审查和分析2型糖尿病患者的胃肠道症状的发生率和严重程度.
- 量化与对照组相比,与蒂尔泽帕提德相关的特定GI副作用的风险.
主要方法:
- 在PubMed,Web of Science和Cochrane图书馆进行了系统的文献搜索.
- 包括六项随机对照试验 (RCT),涉及4,586名患者,遵守PRISMA指南.
- 关于胃肠道症状 (恶心,吐,便秘,腹,消化不良,食欲下降) 的数据被提取并分析.
主要成果:
- 与同类药物相比,提尔泽帕提德显著增加了恶心 (20.43% vs 10.47%),吐 (9.05% vs 4.86%),便秘 (2.54% vs 0.86%),食欲下降 (9.64% vs 2.88%),腹 (16.24% vs 8.63%) 和消化不良 (7.13% vs 3.31%) 的发生率.
- 所有观察到的胃肠道副作用都显示了泽帕提德组的统计学显著增加 (P ≤ 0.0001).
结论:
- 蒂尔泽帕提德的使用与2型糖尿病患者多重胃肠道症状的明显更高的患病率有关.
- 这些发现凸显了关于潜在的胃肠道不良事件的仔细患者咨询的必要性.
- 需要进一步的研究来制定减轻这些副作用的策略,并增强蒂尔泽帕提德的治疗效用.
更多相关视频
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
2.9K
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
270
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
270
01:17Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
01:21Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
136
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
136
01:23Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
01:17Assessment of the Gastrointestinal System I: Subjective Data
202
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
202